What is the clinical evidence from this study?

Study design: Case Report. Population: Atrial fibrillation with life-threatening bleeding during cardiac ablation (n=1). Intervention: Factor Eight Inhibitor Bypassing Activity (FEIBA). Primary outcome: Hemostasis.

What does this research mean for the field?

Low-dose Factor Eight Inhibitor Bypassing Activity (FEIBA) can rapidly reestablish hemostasis in patients experiencing life-threatening bleeding complications while on dabigatran. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.ESTABLISHES_NEW_DIRECTION.

March 8, 2013Critical Care Medicine

Reversing Dabigatran in Life-Threatening Bleeding Occurring During Cardiac Ablation With Factor Eight Inhibitor Bypassing Activity

View Full Paper

Ask AI

Bookmark

Key result

Low-dose FEIBA (26 U/kg) successfully reestablished hemostasis within minutes in a 67-year-old man experiencing life-threatening bleeding during cardiac ablation while on dabigatran.

Why the study?

Does low-dose FEIBA reverse dabigatran-induced life-threatening bleeding during cardiac ablation?

Population

1 67-year-old man with a history of atrial fibrillation with rapid ventricular rate, two previous atrial…

Design

Case_report

Authors

WDWilliam E. DagerUniversity of California, San Francisco RGRobert C. GosselinGhent University Hospital ARA. Joshua RobertsUniversity of California Davis Medical Center

Discussion

Member takes

Implication

Hypothesis-generating for low-dose FEIBA in dabigatran-related ablation bleeding; prospective trials needed before practice change.

Study Design

Type

Case Report (n=1)

Structured PICO

Does low-dose FEIBA reverse dabigatran-induced life-threatening bleeding during cardiac ablation?

Population

1 67-year-old man with a history of atrial fibrillation with rapid ventricular rate, two previous atrial fibrillation ablations, prescribed dabigatran 150 mg bid, who developed transseptal perforation and cardiac tamponade during an ablation procedure.

Intervention

Low-dose Factor Eight Inhibitor Bypassing Activity (FEIBA) (3159 units, 26 U/kg actual body weight) administered over 15 minutes.

Outcome

Hemostasis and cessation of bleedingsafety

Low-dose FEIBA successfully reestablished hemostasis in a patient with life-threatening bleeding from cardiac tamponade during AF ablation while on dabigatran.

Limitations

Single case observation requiring additional studies to confirm findings
Single case observation
Additional studies are warranted to confirm findings

Cite This Study

Dager et al. (2013) conducted a case report in Atrial fibrillation with life-threatening bleeding during cardiac ablation (n=1). Factor Eight Inhibitor Bypassing Activity (FEIBA) was evaluated on Hemostasis. Low-dose FEIBA (26 U/kg) successfully reestablished hemostasis within minutes in a 67-year-old man experiencing life-threatening bleeding during cardiac ablation while on dabigatran.

synapsesocial.com/papers/6a1a0cfe3f3ec013f0df6b5e https://doi.org/10.1097/ccm.0b013e31827caaa3

Topics

Atrial fibrillation Persistent AF management AF ablation outcomes Anticoagulation in AF

View Full Paper

Ask AI

Bookmark

Reversing Dabigatran in Life-Threatening Bleeding Occurring During Cardiac Ablation With Factor Eight Inhibitor Bypassing Activity

Discussion

Member takes

Implication

Study Design

Structured PICO

Limitations

Cite This Study

Topics

Reversing Dabigatran in Life-Threatening Bleeding Occurring During Cardiac Ablation With Factor Eight Inhibitor Bypassing Activity

Discussion

Member takes

Implication

Study Design

Structured PICO

Limitations

Cite This Study

Also Consider

Topics

Also Consider